ABSTRACT Mobilisation of mercury by thiol-complexing agents is the accepted treatment for chronic mercury intoxication. The success of such treatment is judged by the urinary excretion of mercury which might be modified by existing kidney damage caused either by the mercury itself or by other factors. In the present work the ability of three thiol-complexing agents, D-penicillamine, N-acetyl-D, L-penicillamine, and 2,3-dimercaptosuccinic acid (DMSA) to remove mercury from a damaged kidney and to increase the urinary excretion of mercury were studied. Kidney damage was induced by the injection of 20 mg/kg sodium chromate three days before the injection of 2 5 ,moles/kg HgCl2 or three and seven days before the administration of a similar dose of mercury complexed with D-penicillamine.
Except after exposure to short chain alkyl mercurials, mercury in the body is always in the divalent (Hg2+) form that concentrates mainly in the kidneys.' This enables the chelation of Hg2+ after the administration of HgCl2 to be used as a model for mercury mobilisation by thiol-chelating agents irrespective of whether Hg2+ is derived from exposure to mercury vapour or to phenyl-or methoxyethylmercury.
Though the main target in chronic mercury intoxication in man is the central nervous system, ' 2 proteinuria has been occasionally observed in exposed workers.3-6 Moreover, an exposed worker may have kidney damage caused by factors unrelated to mercury. Whether the kidney is damaged by mercury or by other factors, signs and symptoms of mercury intoxication might make chelation treatment desirable. As both the access of the chelator to the renal deposits of mercury and the renal excretion of mercury might be influenced by the condition of the kidneys, the present work is aimed at investigating the effect of three chelating agents on the renal uptake, mobilisation, and excretion of mercury by damaged kidneys. To be able to distinguish between the effects of renal damage and the degree of saturation of the high affinity binding sites for Hg2+ 7 on the mobilisation of mercury by the chelator, the dose of HgCl2 was kept constant, and renal damage was induced by a known nonmercurial nephrotoxin, sodium chromate, which affects the same part of the proximal tubules as HgCl2.8 9 The three chelating agents selected were D-penicillamine, N-acetyl-D,L-penicillamine, and dimercaptosuccinic acid (DMSA). Of The animals were housed individually in metabolic cages and their urine and faeces were collected. They were decapitated 48 or 96 hours after the administration of the mercury; blood was collected from the cervical vein, and the kidneys and liver were removed. The whole body burden of 203Hg was estimated from the y radiation in live animals placed in a 14 x 6 x 6-5 cm plexiglass box between two Nal crystal pairs facing each other with a counting efficiency of 9-6%. Faeces, urine, blood, kidneys, and liver were counted in a well-shaped Nal crystal (diameter 13 cm, depth 11 cm) with an efficiency of 43%.
Results
Pretreatment with sodium chromate decreased the kidney content of mercury and increased the liver and blood contents of mercury at 48 and 96 hours after the injection of HgCl2 (table 1) . Treatment with chelating agents significantly decreased the renal content of mercury in both chromate pretreated and control rats. The order of the efficiency of chelating agents to remove mercury from the kidney was the same in both groups: D-penicillamine <N-acetylpenicillamine <DMSA.
In the chromate pretreated rats, chelation also decreased the blood mercury concentration. Mobilisation of mercury from the kidney did not necessarily increase the urinary excretion of mercury. D-penicillamine and N-acetyl-penicillamine had no effect on the urinary excretion of mercury in either of the two groups, but DMSA increased the urinary mercury excretion by 4-1 times in controls, and by 3-5 times in the pretreated rats (table 2) . By contrast, the faecal excretion of mercury was higher in the pretreated rats than in the controls both during the were also estimated. tSignificantly different (p < 0 05) from saline pretreated rats by the least significant difference method. tSignificant difference (p < 0 05) with the two-way analysis of variance.
significant for liver because the variance was too high. Table 3 also shows that some of the parameters were significantly influenced by the time interval between pretreatment and administration of mercury. There was a significant interaction between pretreatment and time in relation to body burden and urinary mercury excretion at 24 h and body burden and urinary and faecal mercury excretion at 48 h.
Discussion
A short time after the injection of Hg2+ the concentration of mercury in the kidney and the urine can be used as a measure of renal uptake of mercury from the blood. Clearly from the data presented in this paper renal uptake was significantly impaired when mercury was given three days after the injection of 20 mg/kg sodium chromate-that is, in the acute necrotic phase when, according to unpublished observations, the urinary excretion of alkaline phosphatase, glutamic oxalacetic transaminase, and lactic dehydrogenase remained significantly raised. Impaired uptake was noticeable both in HgC12-(tables 1 and 2) and Hg(Pen)2-treated rats (table 3) . When mercury-penicillaminate was given seven days after chromate-that is, in the regenerating phase when tubular cells without a brush border replace damaged cells (unpublished observation by Dr J P R Cabral)-the renal accumulation of mercury was slower but urinary excretion greater than in control rats. Despite the increased urinary excretion the kidney content of mercury hardly decreased from 24 to 48 h in the advanced phase of regeneration while the decrease in kidney mercury contents was 30% or more in control rats or in rats in the acute necrotic phase.
Despite the significant effect of acute renal damage on the renal uptake and the urinary excretion of mercury, the thiol-chelating agents removed mercury to the same extent from the kidneys in relation to the size of the renal mercury deposits in control and chromate-treated rats (table 1) . Of the three compounds tested DMSA was the most efficient and was the only compound that increased the urinary excretion of mercury.
The results presented in this paper indicate that in relation to renal mercury concentrations, chelating agents have the same effect on the mobilisation of mercury from the kidney whether it is damaged or not. In the acute necrotic phase, however, the ability of kidneys to extract mercury both for renal storage and for urinary excretion is impaired, at least in the first 24 hours. With the progress of renal regeneration this effect becomes less pronounced. In the regenerating phase, compared with control kidneys, the accumulation of mercury is somewhat slower, but once mercury is stored in the kidneys its release is also slower.
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